Loading...
XPAR
IPN
Market cap8.43bUSD
Apr 09, Last price  
93.00EUR
1D
-6.34%
1Q
-21.78%
Jan 2017
35.37%
IPO
292.41%
Name

Ipsen SA

Chart & Performance

D1W1MN
P/E
22.22
P/S
2.15
EPS
4.19
Div Yield, %
1.29%
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
5.83%
Revenues
3.57b
+8.11%
788,709,000861,676,000993,757,0001,038,112,0001,112,383,0001,170,298,0001,234,909,0001,277,405,0001,281,800,0001,332,400,0001,520,200,0001,671,100,0002,011,800,0002,348,400,0002,692,800,0002,686,200,0002,748,600,0003,156,400,0003,306,400,0003,574,500,000
Net income
346m
-46.32%
119,230,000144,006,000151,069,000147,669,000157,166,00095,678,000424,000-29,491,000152,540,000153,500,000189,900,000225,900,000272,300,000389,500,000-54,900,000548,000,000646,600,000648,600,000644,400,000345,900,000
CFO
916m
+5.73%
149,553,000327,635,000175,970,000203,409,000257,623,000253,909,000175,446,000144,218,000188,100,000245,800,000223,600,000317,800,000422,900,000570,900,000627,700,000771,300,000871,800,000953,200,000865,900,000915,500,000
Dividend
May 30, 20241.2 EUR/sh
Earnings
May 28, 2025

Profile

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
URL
https://www.ipsen.com/
IPO date
Dec 06, 2005
Employees
5,300
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,574,500
8.11%
3,306,400
4.75%
3,156,400
14.84%
Cost of revenue
2,478,800
2,325,400
2,012,200
Unusual Expense (Income)
NOPBT
1,095,700
981,000
1,144,200
NOPBT Margin
30.65%
29.67%
36.25%
Operating Taxes
74,900
136,200
112,300
Tax Rate
6.84%
13.88%
9.81%
NOPAT
1,020,800
844,800
1,031,900
Net income
345,900
-46.32%
644,400
-0.65%
648,600
0.31%
Dividends
(99,600)
(99,600)
(99,300)
Dividend yield
1.08%
1.11%
1.19%
Proceeds from repurchase of equity
(36,500)
(39,500)
(11,300)
BB yield
0.40%
0.44%
0.14%
Debt
Debt current
37,200
36,400
104,600
Long-term debt
528,300
368,800
667,000
Deferred revenue
36,800
37,700
40,600
Other long-term liabilities
270,200
338,500
232,300
Net debt
(287,900)
(254,900)
(534,000)
Cash flow
Cash from operating activities
915,500
865,900
953,200
CAPEX
(173,000)
(116,200)
(252,900)
Cash from investing activities
(676,600)
(1,072,200)
(458,600)
Cash from financing activities
(100,000)
(458,400)
(146,000)
FCF
931,200
851,600
1,132,400
Balance
Cash
679,200
528,400
1,169,300
Long term investments
174,200
131,700
136,300
Excess cash
674,675
494,780
1,147,780
Stockholders' equity
429,900
3,812,900
3,970,200
Invested Capital
4,485,700
4,011,320
3,139,620
ROIC
24.03%
23.63%
33.82%
ROCE
22.04%
20.73%
26.21%
EV
Common stock shares outstanding
83,392
83,375
83,098
Price
110.70
2.59%
107.90
7.36%
100.50
24.84%
Market cap
9,231,461
2.62%
8,996,185
7.72%
8,351,333
24.45%
EV
8,943,761
8,743,885
7,816,733
EBITDA
1,801,600
1,068,900
1,480,700
EV/EBITDA
4.96
8.18
5.28
Interest
23,800
19,400
23,800
Interest/NOPBT
2.17%
1.98%
2.08%